ADA Exec Chat: Hiten Chawla, Medtronic's VP Of Global Marketing Discusses Diabetes Business Plans
Executive Summary
At this year's American Diabetes Association (ADA) meeting in San Francisco, medtech giant Medtronic made several key announcements including a collaboration with Tidepool Loop, the start of a new patient trial to develop its next-generation hybrid closed-loop system and another trial to improve its sensor technology. Medtech Insight met up with Hiten Chawla, Medtronic's VP of global marketing for its diabetes business, to learn more about these plans.
You may also be interested in...
Market Intel: CGM Market Competition And Device Interoperability Were Hot Topics At ADA2019
Interoperability and the rising use of continuous glucose monitoring is fueling competition among diabetes device-makers and dominated the conversation at the recent annual ADA meeting.
Market Snapshot: Global Insulin Pumps Market Eyes Nearly 10% Growth By 2022
The worldwide insulin pumps market is expected to reach more than $4.5bn by 2022, a CAGR of nearly 10%. This market is largely driven by the rising prevalence of diabetes and the need to control spiraling health-care costs associated with diabetes-related complications. While Medtronic's MiniMed 670G dominates the market, Informa's MedDeviceTracker expects Medtronic will see rising competition from innovative start-ups.
Market Intel: Needle-Free Glucose Monitoring, Digital Solutions Are Game-Changers In Growing Diabetes-Monitoring Market
The global blood glucose monitoring devices market is expected to exceed $7bn by 2022, driven by the smaller, but fastest-growing continuous glucose monitoring (CGM) segment, which is expanding at double-digits. The much bigger blood glucose meter (BGM) segment, meanwhile, is facing increased competition from lower-cost manufacturers, innovative startups and tech giants like Apple that are attracting consumers with smart devices and packaged diabetes management solutions. This first of a two-part series looks more closely at the competitive landscape of the two major product segments – BGM and CGM – with insights from endocrinologists. The second part will focus on the pros and cons of using diabetes management apps and highlights the best diabetes apps.